Exelixis Inc (NASDAQ:EXEL)
| 21.95 Delayed Data As of Dec 01 |  +0.14 / +0.64%Today’s Change | 15.32 Today|||52-Week Range 22.80 | +36.85% Year-to-Date |
Latest EXEL News | Press Releases
| Exelixis (EXEL) Up 8.4% Since Last Earnings Report: Can It Continue? Dec 01 / Zacks.com - Paid Partner Content | Should You Invest in the First Trust NYSE Arca Biotechnology ETF (FBT)? Nov 27 / Zacks.com - Paid Partner Content |
Today’s Trading
| Previous close | 21.81 |
| Today’s open | 21.81 |
| Day’s range | 21.64 - 21.98 |
| Volume | 121,449 |
| Average volume (3 months) | 2,320,451 |
| Market cap | $6.8B |
Data as of 3:59pm ET, 12/01/2023
Growth & Valuation
| Earnings growth (last year) | -22.74% |
| Earnings growth (this year) | +26.53% |
| Earnings growth (next 5 years) | +24.18% |
| Revenue growth (last year) | +12.27% |
| P/E ratio | 75.7 |
| Price/Sales | 3.23 |
| Price/Book | 2.86 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| MEDPMedpace Holdings Inc | +4.85 | +1.79% |
| ---- | ||
| CRLCharles River Labora... | +4.63 | +2.35% |
| ---- |
Data as of 4:00pm ET, 12/01/2023
Financials
| Next reporting date | February 27, 2024 |
| EPS forecast (this quarter) | $0.20 |
| Annual revenue (last year) | $1.6B |
| Annual profit (last year) | $182.3M |
| Net profit margin | 11.31% |
Profile
Sector Health Technology |
Industry Pharmaceuticals: Major |
No executives to display |
Corporate headquarters Alameda, California |
Forecasts
